Publication details
Model ko-kultivace aktivovaných T-lymfocytů s nádorovou buněčnou linií exprimující ligand PD-L1 pro studium potenciace účinku protinádorové imunoterapie
| Title in English | Activated T lymphocyte co-culture model with PD-L1 ligand-expressing tumor cell line to study potentiation of anti-tumor immunotherapy |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Appeared in Conference without Proceedings |
| MU Faculty or unit | |
| Citation | |
| Description | Cancer immunotherapy was one of the breakthroughs in the treatment of cancer. A specific example is the inhibition of immune checkpoints such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) proteins. Tumor cells can suppress the anti-tumor immune response by increasing the expression of PD-L1, which subsequently interacts with the PD-1 receptor expressed by T-lymphocytes; therefore, targeted inhibition of these checkpoints is effective in cancer therapy. Approaches that could enhance the effect of cancer immunotherapy or ways to overcome resistance to this type of therapy are currently being explored. An example would be the use of synergism of checkpoint inhibitors with inhibitors of signal transducer and activator of transcription (STAT3), which acts as a regulator of PD-L1 checkpoint expression. The aim of this project was to validate a model of co-culture of the tumor cell line DU-145, expressing the PD-L1 ligand, simultaneously with activated T-lymphocytes. This model is to be used to evaluate the potential of the test compounds to induce an increase in cytotoxic T-lymphocyte activity in response to changes in the number of PD-L1 ligands in tumor cells. Thus, the functionality of the model was verified in this project and it can be used to further study the potentiation of the effects of anti-cancer immunotherapy. |
| Related projects: |